| abstract |
The present invention relates to markers for high-grade serous ovarian cancer (HG-SOC) and methods and uses thereof for diagnosing high-grade serous ovarian cancer (HG-SOC) and/or determining the prognosis of a subject suffering from high-grade serous ovarian cancer (HG-SOC) by determining the presence or absence of a mutation in a CHEK2 marker or mutations of markers from a 21-gene panel comprising ADAMTSL3, ATR, CHEK2, ENAH, ERN2, GLI2, GYPB, KIAA1324L, LRRN2, MAP3K6, MAPK15, MET, MLL4, NIPBL, PCDH15, PPP1CC, PTCH1, PTK2B, RPS6KA2, RSU1 and TNC. It also relates to the use of markers CHEK2, RPS6KA2 and MLL4 in predicting the risk of developing high-grade ovarian serous ovarian cancer by determining germline mutations in at least one of these three markers. |